drugset / Trial / NCT01433523
House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma
Phase 3
Completed
834 enrolled
ALK-Abelló A/S
ACM Pivotal Global Central Laboratory · collabErgomed GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to investigate if treatment with house dust mite allergen immunotherapy tablet can reduce the risk of asthma exacerbation in subjects with house dust mite induced asthma.
Timeline
- Start
- 2011-08
- Primary completion
- 2013-04
- Completion
- 2014-02
Publications
- Hoof I, Bonnelykke K, Stranzl T, Brand S, Li X, Shamji MH, Meyers DA, Bateman ED, Bleecker E, Andersen PS. Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma. Thorax. 2024 Mar 15;79(4):332-339. doi: 10.1136/thorax-2023-220707.
- Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD011293. doi: 10.1002/14651858.CD011293.pub3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALK HDM AIT | Unknown | 6 unknown | Other |
| Subject | ALK HDM AIT | Unknown | 12 unknown | Other |